Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for adult refractory nephrotic syndrome
ChiCTR2000031963Phase 4Recruiting
- Sponsor
- 万启军
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in nephrosis and nephrotic syndrome (NS) (2 arms), sponsored by 万启军. Primary endpoint: Disease remission. Started Jul 2020; status: recruiting.
02
Drugs
rituximab
03
Conditions
nephrosisnephrotic syndrome (NS)
Beyond the preview
Go deeper on ChiCTR2000031963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031963.